12 results about "Interstitial pneumonia" patented technology

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention provides a method and a system for diagnosing interstitial pneumonia after new crown infection by using multi-modal fusion, which are combined with multi-modal data (text, image and inspection), extract clinical text features by using BERT, process image information by combining Swin-Transform, and perform multi-modal feature fusion through a dynamic fusion learning algorithm, so that the diagnosis precision and specificity are remarkably improved, and the diagnosis accuracy and the diagnosis specificity are improved. According to the method, the limitation of traditional single-mode analysis is broken through, compared with a single-mode diagnosis method, the diagnosis accuracy of a multi-mode fusion model on a test set is improved by about 15%, misdiagnosis and missed diagnosis are reduced, and through automatic and objective AI diagnosis, misdiagnosis and missed diagnosis conditions caused by human factors are reduced.

The invention pertains to the field of pharmacology and medicine, specifically to the use of the IL-6 inhibitor olokizumab for the treatment of progressive fibrotic interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, lymphocytic interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, hypersensitivity pneumonitis (allergic alveolitis), sarcoidosis; interstitial pneumonia with autoimmune features; pneumoconioses; pulmonary histiocytosis; interstitial lung disease associated with autoimmune diseases, such as systemic sclerosis; rheumatoid arthritis; systemic lupus erythematosus; polymyositis / dermatomyositis; primary Sjögren's syndrome; mixed connective tissue disease; other systemic connective tissue diseases, as well as polymyalgia rheumatica and giant cell arteritis. This disclosure can be used for the effective therapy of progressive fibrotic ILDs, as polymyalgia rheumatica, and giant cell arteritis expanding the range of medications used to treat these conditions.

The present disclosure relates to compounds of Formula (A) and Formula (I), for example: (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi and avPe integrin. Also disclosed are methods of treating fibrosis, such as non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and non-specific interstitial pneumonia (NSIP), as well as cancer, comprising administering the compounds and pharmaceutical compositions thereof.

The present application relates to the technical field of pharmaceutical preparations, in particular to a powder aerosol intermediate composition and a preparation method thereof, a sodium ciprofloxacin inhalation powder aerosol and an application thereof. The raw and auxiliary materials of the intermediate composition include 1-7 wt% of sodium ciprofloxacin, 92-98 wt% of lactose and not more than 1% of magnesium stearate, in terms of mass percentage fraction; the D 50 of the sodium ciprofloxacin is 1-5 microns; the D 50 of the lactose is 100-150 microns. The intermediate composition can be used for preparing the sodium ciprofloxacin inhalation powder aerosol, and can realize efficient delivery of the sodium ciprofloxacin, improve the delivery efficiency of the sodium ciprofloxacin at a target site, and reduce systemic side effects. The sodium ciprofloxacin inhalation powder aerosol can be used for treating mild diseases such as cystic fibrosis, interstitial pneumonia and idiopathic pulmonary fibrosis, and thus expands the indications of the sodium ciprofloxacin.

The present invention refers to an agent for use in the prevention and / or treatment of lung pathological conditions associated with loss of alveolar epithelial type II to type I trans- differentiation capacity and / or with loss of lung regenerative capacity and / or for use in promoting lung regeneration in a subject with a lung pathological condition, said agent being selected from the group consisting of: an inhibitor of miR-210-3p and an inhibitor of miR-155- 5p or a combination thereof, wherein said lung pathological condition is selected from the group consisting of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis-ILD, cryptogenic organizing pneumonia and acute interstitial pneumonia, chronic obstructive pulmonary disease, post-acute respiratory distress syndrome, and post-acute COVID-19 syndrome.

The present invention relates to compounds of formula (A) and compounds of formula (I): or salts thereof, wherein R 1 、R 2 、R 10 、R 11 、R 12 、R 13 、R 14 、R 15 、R 16 、q and p are as described herein. The compounds of formula (A), the compounds of formula (I), and their pharmaceutical compositions are αvβ6 integrin inhibitors, which can be used for the treatment of fibrosis, such as idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP).

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a Huihui decoction and application thereof in treating interstitial pneumonia. The Huhui decoction is prepared from radix bupleuri, radix paeoniae rubra, fructus aurantii immaturus, fructus perillae, rhizoma pinelliae, cortex magnoliae officinalis, apricot kernels and radix glycyrrhizae, has the effects of soothing the liver, regulating the lung and promoting qi to activate blood and can be used for treating various symptoms such as liver depression, lung closure, qi stagnation and blood stasis. Clinical practices show that the traditional Chinese medicine composition can be added or reduced along with symptoms on the basis of the traditional Chinese medicine composition, can effectively relieve clinical symptoms of ILD patients, and has a good application prospect. Animal experiments prove that the loopback decoction has a definite overall treatment effect on multi-phenotype abnormalities such as joint inflammation and pulmonary function impairment of RA-ILD mice, and can effectively improve joint inflammation, pulmonary fibrosis and abnormal inflammatory response caused by RA-ILD.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from benidipine, folic acid substances and acceptable auxiliary materials. The ratio range of the benidipine to the folic acid is (2-10): (0.2-2.0) according to the content of the benidipine and the folic acid. The pharmaceutical composition has the advantages that the pharmaceutical composition can inhibit pulmonary fibrosis, can be provided for pulmonary fibrosis high-risk groups such as pulmonary tuberculosis, chronic bronchitis, interstitial pneumonia and silicosis, and is used for preventing or treating pulmonary fibrosis. In addition, the compound form of the pharmaceutical composition is beneficial to improving the curative effect, reducing the side effect and increasing the medication compliance.